Transdermal Delivery of PCSK9 siRNA via Biomimetic Nanovesicle‐Loaded Microneedles for Psoriasis Immunomodulation
Advanced Healthcare Materials · 2026-03 · 15 (10)
DOI: 10.1002/adhm.202504232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 18.12.2025. Verfasst von Hanxue Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei, China. Hauptthemen laut MEDLINE: Psoriasis, Proprotein Convertase 9, RNA, Small Interfering, Immunomodulation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Psoriasis onset is closely associated with abnormal lipid metabolism. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a pivotal regulator of lipid metabolism, has recently been implicated in keratinocyte hyperproliferation and immune dysregulation in psoriasis.However, transdermal delivery of siRNAs forPCSK9 inhibition is challenging.To address this limitation, we developed a dissolvable microneedle (MN) platform encapsulating mesenchymal stem cell (MSC)‐derived biomimetic nanovesicles (MSCNV) loaded with siPCSK9 (MN‐MSCNV@siPCSK9). This integrated platform facilitates stabilized siRNA encapsulation via MSCNV‐mediated protection, enables efficient transdermal delivery via stratum corneum disruption, and leverages MSCNV's inherent bioactivity for synergistic immunomodulation. In vitro, MN‐MSCNV@siPCSK9 significantly inhibited keratinocyte proliferation and pro‐inflammatory cytokine secretion. In vivo, it alleviated imiquimod (IMQ)‐induced psoriasis symptoms by reducing epidermal hyperplasia and systemic inflammation. Mechanistically, the platform suppressed nuclear factor‐kappa B (NF‐κB) pathway activation, modulated Th1, Th2, and Th17 cell subsets, and disrupted the inflammatory crosstalk between keratinocytes and immune cells. Consequently, it coordinately regulates both local and systemic inflammatory microenvironments. This study establishes a translatable “encapsulation‐delivery‐modulation” strategy, providing a potent gene‐silencing platform for precision psoriasis therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Anhui Medical University, Hefei, China.
- School of Medicine, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
- Shanghai Engineering Research Center of External Chinese Medicine, Shanghai, China.
ORCID-Profile: Quangang Zhu, Zongguang Tai, Zhongjian Chen
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Municipal Health Commission
Zitieren
APA
Zhou, H., Lu, J., Yin, B., Meng, Y., Zhu, C., Wu, X., Liu, J., Zhu, Q., Tai, Z., & Chen, Z. (2026). Transdermal Delivery of PCSK9 siRNA via Biomimetic Nanovesicle‐Loaded Microneedles for Psoriasis Immunomodulation. Advanced Healthcare Materials, 15(10). https://doi.org/10.1002/adhm.202504232
Vancouver
Zhou H, Lu J, Yin B, Meng Y, Zhu C, Wu X, et al. Transdermal Delivery of PCSK9 siRNA via Biomimetic Nanovesicle‐Loaded Microneedles for Psoriasis Immunomodulation. Advanced Healthcare Materials. 2026;15(10). doi:10.1002/adhm.202504232
BibTeX
@article{Zhou2026,
author = {Zhou, Hanxue and Lu, Jiaye and Yin, Bei and Meng, Yu and Zhu, Congcong and Wu, Xiying and Liu, Jun and Zhu, Quangang and Tai, Zongguang and Chen, Zhongjian},
title = {Transdermal Delivery of PCSK9 siRNA via Biomimetic Nanovesicle‐Loaded Microneedles for Psoriasis Immunomodulation},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {10},
doi = {10.1002/adhm.202504232}
}
EUVIMED